Back to discover
Disease

Pregnancy in Obesity

Late-stage therapeutic developmentEmerging research
MeSHPregnancy in Obesity
2
Publications
24
Clinical trials
2025
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment.

Research2025-09-24Best practice & research. Clinical endocrinology & metabolism

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: High
Key developments
  • 6 clinical trials expected to report results, the earliest in Q2 2027.
Upcoming Milestones
Clinical Milestones18View all 18
Results posted 1
Results expected 5
Recently completed 5
Other updates 5
+10 more in the activity timeline below
Activity timeline18

Clinical trials

13 sponsors · 5 new · 6 completed in the last 12 months (net +4)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c.2.4 mg Once-weekly

Phase 4 · Active, not recruiting · Novo Nordisk A/S

A Novel Precision Medicine Approach For Obesity: A Randomized, Multi-Center Trial

Phase 4 · Active, not recruiting · Mayo Clinic

EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY-BIASED ULTRA LONG-ACTING GLP-1RA, IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)

Phase 3 · Active, not recruiting · Pfizer

Efficacy, Metabolic and Cardiovascular Effects of Liraglutide in Children Aged 6-12 Years With Severe Obesity: A Randomized Controlled Trial With Advanced Echocardiographic Assessment

Phase 4 · Active, not recruiting · University of Sao Paulo General Hospital

A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial

Phase 3 · Active, not recruiting · Eli Lilly and Company

Long-term Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Placebo in Participants With Obesity

Phase 3 · Active, not recruiting · Novo Nordisk A/S
Recently completed

Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)

Phase 3 · Completed · University of Colorado, Denver

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial

Phase 3 · Completed · Eli Lilly and Company

Pharmacological and Behavioral Treatments to Treat Loss-of-Control Eating and Improve Weight Outcomes After Bariatric Surgery: Acute (Stage 1)

Phase 2/3 · Completed · Yale University

A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HRS-7535 Tablets in Subjects With Overweight or Obesity

Phase 3 · Completed · Shandong Suncadia Medicine Co., Ltd.

Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO)

Phase 3 · Completed · Eli Lilly and Company

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial: Multiple Independent Sub-studies of Setmelanotide in Patients With POMC/PCSK1, LEPR, NCOA1(SRC1), or SH2B1 Gene Variants in the Melanocortin-4 Receptor Pathway

Phase 3 · Completed · Rhythm Pharmaceuticals, Inc.

Evidence coverage

8 treatments

How much of this condition's readable clinical evidence the confidence engine has incorporated, across its most-studied treatments. This measures coverage of the evidence base — not whether any treatment works.

Partial evidence coverage
52% · 124/240 eligible items incorporated

Largest gap: off claim endpoint family (8, endpoint-family).

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
2019–2025
Most influential

Determinants of Maternal Insulin Resistance during Pregnancy: An Updated Overview.

Journal of diabetes research · 2019 · 222 cites
Recent publications

Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment.

Best practice & research. Clinical endocrinology & metabolism · 2025

Determinants of Maternal Insulin Resistance during Pregnancy: An Updated Overview.

Journal of diabetes research · 2019 · 222 cites
Major themes8
  • Anti-Obesity Agents1
  • Diet1
  • Glucagon-Like Peptide 11
  • Glucagon-Like Peptide-1 Receptor Agonists1
  • Insulin Resistance1
  • Obesity1
  • Preconception Care1
  • Pregnancy in Obesity1
Leading journals2
  • Best practice & research. Clinical endocrinology & metabolism1
  • Journal of diabetes research1
Leading researchers7
  • Fuglsang J1
  • Janež A1
  • Jensterle M1
  • Kampmann U1
  • Knorr S1
  • Koceva A1
  • Ovesen P1
Affiliations (unnormalised)4
  • Aarhus University Hospital1
  • Steno Diabetes Center Aarhus1
  • University Medical Center Ljubljana1
  • University Medical Center Maribor1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

BODY MASS INDEX in PREGNANT PEOPLE that is excessively above the recommended cut-off.

Identifiers
MeSHPregnancy in Obesity
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.